1. Everolimus-eluting stent versus bare metal stent in proximal left anterior descending ST-elevation myocardial infarction: insights from the EXAMINATION trial
- Author
-
Josep, Gomez-Lara, Salvatore, Brugaletta, Joan-Antoni, Gomez-Hospital, Jose Luis, Ferreiro, Gerard, Roura, Rafael, Romaguera, Victoria, Martin-Yuste, Monica, Masotti, Andrés, Iñiguez, Antonio, Serra, Rosana, Hernandez-Antolin, Vicente, Mainar, Marco, Valgimigli, Maurizio, Tespili, Pieter, den Heijer, Armando, Bethencourt, Nicolás, Vazquez, Patrick, Serruys, Manel, Sabate, and Angel, Cequier
- Subjects
Male ,Sirolimus ,Myocardial Infarction ,Drug-Eluting Stents ,Middle Aged ,Coronary Angiography ,Survival Rate ,Electrocardiography ,Treatment Outcome ,Spain ,Myocardial Revascularization ,Humans ,Female ,Everolimus ,Prospective Studies ,Immunosuppressive Agents ,Follow-Up Studies - Abstract
ST-elevation myocardial infarctions (STEMI) caused by proximal left-anterior descending (LAD) lesions have more myocardium at risk and worse outcomes than those located in other segments. The aim is to compare outcomes of patients with STEMI and proximal-LAD lesions treated with bare-metal stents (BMS) versus everolimus-eluting stents (EES).The EXAMINATION trial randomized 1498 STEMI patients to BMS versus EES. The primary end point was the patient-oriented combined of all-cause death, any-recurrent myocardial infarction (MI) and any-revascularization. The secondary end point included the device-oriented combined of cardiac death, target-vessel MI and target-lesion revascularization (TLR).STEMI with a proximal-LAD occlusion was observed in 290 patients (BMS = 132 and EES = 158). Both groups were similar except for diabetes (12.9% vs 24.1%; P = .016). At 1 year, the primary end point was observed in 18.9% and 9.5% of patients treated with BMS and EES, respectively (P = .023). The secondary end point was observed in 11.4% and 5.1%, respectively (P = .053). There were no differences in cardiac death (4.5% vs 3.8%; P = .750) and MI (1.5% vs 0%; P = .121). BMS had higher rate of TLR compared to EES (6.8% vs 1.3%; P = .014). Patients with proximal-LAD STEMI had higher mortality than patients with non proximal-LAD STEMI (5.5% vs 2.9%; P = .027). Proximal-LAD lesions treated with BMS tended to increase the risk of the primary end point compared with other segments (18.9% vs 13.0%; P = .079). However, EES implanted in proximal-LAD had similar outcomes compared with other locations (9.5% vs 12.0%; P = .430). Adjusting for confounders, the interaction between BMS and proximal-LAD location was associated with the primary end point.Patients with STEMI and proximal-LAD lesions treated with EES have better outcomes compared with BMS at 1 year. Although further investigations are required, it seems reasonable to consider EES for proximal-LAD STEMI-lesions.
- Published
- 2012